Alzheimer’s disease risk variants show association with cerebrospinal fluid amyloid beta

被引:0
|
作者
John S. K. Kauwe
Jun Wang
Kevin Mayo
John C. Morris
Anne M. Fagan
David M. Holtzman
Alison M. Goate
机构
[1] B8134 Washington University School of Medicine,Department of Psychiatry
[2] Washington University School of Medicine,Department of Neurology
[3] Washington University School of Medicine,Alzheimer’s Disease Research Center
[4] Washington University School of Medicine,Hope Center for Neurological Disorders
[5] Washington University School of Medicine,Department of Molecular Biology and Pharmacology
[6] Washington University School of Medicine,Department of Pathology and Immunology
[7] Washington University School of Medicine,Department of Genetics
来源
neurogenetics | 2009年 / 10卷
关键词
Amyloid beta; Alzheimer’s disease; Genetics; Association; Transferrin;
D O I
暂无
中图分类号
学科分类号
摘要
The use of quantitative endophenotypes in genetic studies may provide greater power, allowing for the use of powerful statistical methods and a biological model for the effects of the disease-associated genetic variation. Cerebrospinal fluid (CSF) amyloid beta (Aβ) levels are promising endophenotypes for late-onset Alzheimer’s disease (LOAD) and show correlation with LOAD status and Aβ deposition. In this study, we investigated 29 single nucleotide polymorphisms (SNPs) positive in AlzGene (http://www.alzgene.org) meta-analyses, for association with CSF Aβ levels in 313 individuals. This study design makes it possible to replicate reported LOAD risk alleles while contributing novel information about the mechanism by which they might affect that risk. Alleles in ACE, APOE, BDNF, DAPK1, and TF are significantly associated with CSF Aβ levels. In vitro analysis of the TF SNP showed a change in secreted Aβ consistent with the CSF phenotype and known Alzheimer’s disease variants, demonstrating the utility of this approach in identifying SNPs that influence risk for disease via an Aβ-related mechanism.
引用
收藏
页码:13 / 17
页数:4
相关论文
共 50 条
  • [1] Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta
    Kauwe, John S. K.
    Wang, Jun
    Mayo, Kevin
    Morris, John C.
    Fagan, Anne M.
    Holtzman, David M.
    Goate, Alison M.
    [J]. NEUROGENETICS, 2009, 10 (01) : 13 - 17
  • [2] Cerebrospinal fluid amyloid beta and tau protein: biomarkers for Alzheimer's disease
    Mandic, Gorana
    Markovic, Ivanka
    Ostojic, Marija
    Stojkovic, Tanja
    Misirlic-Dencic, Sonja
    Zivanovic-Radnic, Tatjana
    Stefanovic, Rodoljub
    Bumbasirevic, Marko
    Stefanova, Elka
    Kostic, Vladimir
    [J]. VOJNOSANITETSKI PREGLED, 2008, 65 (12) : 901 - 905
  • [3] Cerebrospinal fluid sphingolipids, β-amyloid, and tau in adults at risk for Alzheimer's disease
    Mielke, Michelle M.
    Haughey, Norman J.
    Bandaru, Veera. V. R.
    Zetterberg, Henrik
    Blennowd, Kaj
    Andreasson, Ulf
    Johnson, Sterling C.
    Gleason, Carey E.
    Blazel, Hanna M.
    Puglielli, Luigi
    Sager, Mark A.
    Asthana, Sanjay
    Carlsson, Cynthia M.
    [J]. NEUROBIOLOGY OF AGING, 2014, 35 (11) : 2486 - 2494
  • [4] Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease
    Southwick, PC
    Yamagata, SK
    Echols, CL
    Higson, GJ
    Neynaber, SA
    Parson, RE
    Munroe, WA
    [J]. JOURNAL OF NEUROCHEMISTRY, 1996, 66 (01) : 259 - 265
  • [5] Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease
    Tamaoka, A
    Sawamura, N
    Fukushima, T
    Shoji, S
    Matsubara, E
    Shoji, M
    Hirai, S
    Furiya, Y
    Endoh, R
    Mori, H
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 1997, 148 (01) : 41 - 45
  • [6] Sphingolipid Metabolism Correlates with Cerebrospinal Fluid Beta Amyloid Levels in Alzheimer's Disease
    Fonteh, Alfred N.
    Ormseth, Cora
    Chiang, Jiarong
    Cipolla, Matthew
    Arakaki, Xianghong
    Harrington, Michael G.
    [J]. PLOS ONE, 2015, 10 (05):
  • [7] β-amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease
    Andreasen, N
    Blennow, K
    [J]. PEPTIDES, 2002, 23 (07) : 1205 - 1214
  • [8] Cerebrospinal fluid sphingolipids and acid sphingomyelinase change with beta amyloid levels in Alzheimer's disease
    Ormseth, Cora
    Chiang, Jiarong
    Arakaki, Xianghong
    Harrington, Michael
    Fonteh, Alfred
    [J]. FASEB JOURNAL, 2014, 28 (01):
  • [9] Cerebrospinal Fluid Amyloid Beta, MRS Brain Metabolites in Alzheimer's Disease: A Systematic Review
    Piersson, Albert Dayor
    Mohamad, Mazlyfarina
    Rajab, Fadilah
    Suppiah, Subapriya
    [J]. ACADEMIC RADIOLOGY, 2021, 28 (10) : 1447 - 1463
  • [10] GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer's Disease
    Cruchaga, Carlos
    Kauwe, John S. K.
    Harari, Oscar
    Jin, Sheng Chih
    Cai, Yefei
    Karch, Celeste M.
    Benitez, Bruno A.
    Jeng, Amanda T.
    Skorupa, Tara
    Carrell, David
    Bertelsen, Sarah
    Bailey, Matthew
    McKean, David
    Shulman, Joshua M.
    De Jager, Philip L.
    Chibnik, Lori
    Bennett, David A.
    Arnold, Steve E.
    Harold, Denise
    Sims, Rebecca
    Gerrish, Amy
    Williams, Julie
    Van Deerlin, Vivianna M.
    Lee, Virginia M. -Y.
    Shaw, Leslie M.
    Trojanowski, John Q.
    Haines, Jonathan L.
    Mayeux, Richard
    Pericak-Vance, Margaret A.
    Farrer, Lindsay A.
    Schellenberg, Gerard D.
    Peskind, Elaine R.
    Galasko, Douglas
    Fagan, Anne M.
    Holtzman, David M.
    Morris, John C.
    Goate, Alison M.
    [J]. NEURON, 2013, 78 (02) : 256 - 268